Lilly, Daiichi Sankyo Suspend Enrollment In Phase II Trials Of Prasugrel
This article was originally published in The Pink Sheet Daily
Executive Summary
Analysis of “a number of studies” underlies decision to temporarily suspend enrollment to consider dosing changes for the anti-platelet therapy, Lilly tells “The Pink Sheet” DAILY.
You may also be interested in...
Lilly’s Prasugrel Superior To Bristol’s Plavix In Reducing CV Events In Pivotal TRITON Trial
Efficacy tempered by an increase in non-CABG bleeding compared to clopidogrel.
Lilly’s Prasugrel Superior To Bristol’s Plavix In Reducing CV Events In Pivotal TRITON Trial
Efficacy tempered by an increase in non-CABG bleeding compared to clopidogrel.
Bristol Halts Development Of Vinflunine In Bladder Cancer
Company is in discussions with FDA regarding novel cytotoxic, but does not expect to file an NDA for bladder cancer; vinflunine program also includes lung and breast cancer studies.